|

Endocrine therapy + Abemaciclib Clinical Trials

1 actively recruiting trial

Pipeline

Phase 3: 1

Top Sponsors

  • Japanese Foundation for Cancer Research1

Indications

  • Locoregional Recurrence1
  • Endocrine Therapy1
  • Abemaciclib1
  • Breast Cancer1
  • Cancer1

Other1 trial

Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.